CalciMedica Inc. Common Stock (CALC)
Stock · NASDAQ · Health Care
$1.04as of 10/16/2026
Price chart
Active signals
CALC Signal Track Record
How signals performed across all stocks →What CALC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -3.0% | 47% | October 8, 2026 |
| Bollinger Band Breakout | 15 | -12.3% | 27% | August 31, 2026 |
| Bollinger Band Breakdown | 9 | +5.5% | 56% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -1.7% | 40% | October 5, 2026 |
| Any 20-session window (baseline) | -4.0% | 42% |
Computed by MarketWall from daily closing prices since April 1, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CALC
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidne…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 15
- Website
- calcimedica.com/
Fundamentals
- 1-day range
- $1.19$1.28
- Market cap
- $21.88M
- P/E (trailing)
- —
- P/E (forward)
- -0.74
- EPS (trailing)
- $-1.34
- Dividend yield
- —
- Beta
- 0.78
- Avg. volume
- 75.6K
Forecasts
3 analyst ratings
CalciMedica Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CALCCalciMedica Inc. Common Stock$1.04▼ 3.70%Market cap $21.88MP/E —$1.27$36
- ALLRAllarity Therapeutics Inc. Common Stock$0.895▲ 7.44%Market cap $21.65MP/E —$0.769$1.84
- NEUPNeuphoria Therapeutics Inc. Common Stock$3.3▼ 0.30%Market cap $21.08MP/E —$3.19$17.9
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
- ATOSAtossa Therapeutics Inc. Common Stock$2.91▲ 9.81%Market cap $20.84MP/E —$1.7$16.5
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$2.47▼ 8.86%Market cap $20.67MP/E —$2.85$23.1
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CALC CalciMedica Inc. Common Stock | $21.88M | — | $1.04 | ▼ 3.70% | $1.27$36 |
| ALLR Allarity Therapeutics Inc. Common Stock | $21.65M | — | $0.895 | ▲ 7.44% | $0.769$1.84 |
| NEUP Neuphoria Therapeutics Inc. Common Stock | $21.08M | — | $3.3 | ▼ 0.30% | $3.19$17.9 |
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
| ATOS Atossa Therapeutics Inc. Common Stock | $20.84M | — | $2.91 | ▲ 9.81% | $1.7$16.5 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $20.67M | — | $2.47 | ▼ 8.86% | $2.85$23.1 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CalciMedica Files Prospectus Supplement For Up To $25M At-The-Market Common Stock OfferingBenzinga · 9/30/2026
- CalciMedica Regains Nasdaq ComplianceBenzinga · 9/16/2026
Insider Activity
Insider Actions →- Guerard Frederic · October 1, 2026 · Grant20.0K
- Glicklich Alan · October 1, 2026 · Grant20.0K
- Zaytsev Evgeny · October 1, 2026 · Grant20.0K
- Shaw Allan · October 1, 2026 · Grant20.0K
- Robert N. Wilson · October 1, 2026 · Grant20.0K
- Kenneth A. Stauderman · September 24, 2026 · Grant180.0K
- Sudarshan Hebbar · September 24, 2026 · Grant180.0K
- Stephen Bardin · September 24, 2026 · Grant190.0K
- A. Rachel Leheny · September 24, 2026 · Grant360.0K
- ALAFI CAPITAL CO LLC · August 19, 2026 · Grant3.53M
- Sudarshan Hebbar · August 19, 2026 · Grant124.5K
- Guerard Frederic · August 19, 2026 · Grant10.0K
- Glicklich Alan · August 19, 2026 · Grant10.0K
- Zaytsev Evgeny · August 19, 2026 · Grant10.0K
- Zaytsev Evgeny · August 19, 2026 · Grant1.45M
Institutional Ownership
March 31, 2026
- Total shares held
- 1.07M
- Total value held
- $501.7K
- Institutional holders
- 27
- Unknown178.5K
- Unknown169.1K
- Unknown128.1K
- Unknown126.5K
- Unknown123.4K
- Unknown60.0K
- Unknown53.7K
- Unknown39.7K
- Unknown30.7K
- Unknown23.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
CALC files prospectus supplement for $25M ATM offering
CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.
CALC files prospectus supplement for $25M ATM offering. CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.